

## Product Sheet Dupixent

### 1. General Product Information

- Human IgG monoclonal antibody that inhibits the activation of the IL-4 and IL-13 pathways.
- IL-4 and IL-13 are major drivers of type 2 inflammation, which plays a significant role in AD, asthma, and CRSwNP.
- Provides rapid, sustained, and clinically significant long-term improvement in disease control parameters, including signs, symptoms, and quality of life, across a wide range of diseases with type 2 inflammation.

### 2. Therapeutic Indications

- Indicated for the treatment of patients aged 6 months and older with moderate to severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
- Dupixent can be used with or without topical therapy (topical corticosteroids).
- First-line systemic treatment for moderate to severe AD with the best clinical profile, balancing rapid and sustained efficacy with reliable long-term safety.

### 3. Benefits

- Rapid efficacy (after the first dose) and sustained long-term (up to 3 years) in signs, symptoms, and quality of life.
- Long-term reliable safety up to 3 years.

### 4. Evidence

- The recent positive phase III result in infants (<6 years) further reinforces the extraordinary efficacy and safety of DUPIXENT across all age groups.

## Questions for Exploration:

- Do you have patients with uncontrolled moderate to severe atopic dermatitis?
- How do you determine the severity of the disease?
- When discussing control, what factors do you consider to determine if a patient is controlled?
- Do you have patients with relapses? How often do they experience relapses? What do your patients express when they experience relapses?

**Value Dialogue Against the Competition:** Absolutely, I understand your interest in exploring more options for your patients. I would like to highlight that Dupixent offers rapid and sustained improvements in atopic dermatitis, backed by studies showing up to 3 years of efficacy and safety. Unlike Abrocitinib, Dupixent is a monoclonal antibody that specifically

inhibits the IL-4 and IL-13 pathways, suitable for patients with type 2 diseases. Additionally, Dupixent is injectable, which may be a convenient option for some patients compared to the oral administration of Abrocitinib. Dr. Julia, do you have any other questions about Dupixent?